Frontiers in Aging Neuroscience
February 10, 2022
K. Watson, Angela D Bryan, R. Thayer et al.
Several lines of evidence suggest that older adults (aged 65+) sharply increased their cannabis use over the last decade, highlighting a need to understand the effects of cannabis in this age group. Pre-clinical models suggest that cannabinoids affect the brain and cognition in an age-dependent fashion, having generally beneficial effects on older animals and deleterious effects on younger...
Stroke
February 10, 2022
Fernando D. Testai, Philip B. Gorelick, Hugo J. Aparicio et al.
50 citations
Marijuana is perceived as a harmless drug, and its recreational use has gained popularity among young individuals. The concentration of active ingredients in recreational formulations has gradually increased over time, and high-potency illicit cannabinomimetics have become available. Thus, the consumption of cannabis in the general population is rising. Data from preclinical models demonstrate...
American Journal of Psychiatry
February 2022
Kevin P Hill, Mark S. Gold, Charles B. Nemeroff et al.
The United States is in the midst of rapidly changing laws regarding cannabis. The increasing availability of cannabis for recreational and medical use requires that mental health clinicians be knowledgeable about evidence to be considered when counseling both patients and colleagues. In this review, the authors outline the evidence from randomized double-blind placebo-controlled trials for...
International Journal of Drug Policy
February 2022
Pieter E Oomen, Dominique Schori, Karsten Tögel-Lins et al.
European drug checking services exchange information on drug trends within the Trans European Drug Information (TEDI) network, allowing monitoring and coordination of responses. Starting in Spring 2020, several services detected the synthetic cannabinoid receptor agonist MDMB-4en-PINACA in adulterated low-THC cannabis products. Cannabis products suspected of adulteration were analyzed for the...
Psychophysiology
February 2022
Elisa Pabon, Frederica Rockwood, Greg J Norman et al.
Cannabis is the most commonly used psychotropic drug in the United States, after alcohol. Despite its apparent sedative and calming effects, cannabis and its main psychoactive constituent, ∆9 -tetrahydrocannabinol (THC) can produce serious adverse effects including tachycardia and anxiety. These effects can be especially pronounced in women, who remain underrepresented in clinical cannabinoid...
medRxiv
January 31, 2022
Deepak Cyril D’souza, Justin Raj, Suhas Ganesh et al.
preprint
Abstract Introduction Cannabis use has been associated with several psychosis outcomes including acute and persistent psychosis termed Cannabis Induced Psychotic Disorder (CIPD). The clinical and cognitive profile, course of CIPD, and the extent to which it is different from psychosis unrelated to cannabis exposure (PsyNoCan) is not clear. Methods The acute presentation and short-term (∼4...
Frontiers in Psychiatry
January 21, 2022
Melina Wiedmann, Sören Kuitunen-Paul, Lukas A Basedow et al.
5 citations
ObjectivesBoth substance use, on the one hand, and the first signs of psychosis, on the other, commonly begin in adolescence. Adolescents with substance use disorder (SUD) frequently show recreational use of cannabis and 3,4-methylenedioxymethamphetamine (MDMA). When attenuated psychotic symptoms (APS) occur during the course of SUD, they are commonly attributed to the cannabis use, neglecting...
Addiction
January 19, 2022
Laura Dellazizzo, Stéphane Potvin, S. Giguère et al.
BACKGROUND Cannabis is among the most consumed psychoactive substances world-wide. Considering changing policy trends regarding the substance, it is crucial to understand more clearly its potential acute and residual adverse effects from a public health viewpoint. Cognitive function is one of the targeted areas with conflicting findings. This meta-review measured the magnitude of acute and...
Schizophrenia Research: Cognition
January 5, 2022
Christopher Dawes, Declan Quinn, Andrea Bickerdike et al.
Aberrant salience processing may underlie the link between cannabis and psychosis, as posited in individuals with schizophrenia or high schizotypy. We investigated the relative effects of cannabis use, schizotypy status, and self-reported aberrant salience experiences on salience processing, measured using a latent inhibition (LI) task (Granger et al., 2016), in a non-clinical population. A...
Journal of Cannabis Research
January 4, 2022
J. Kruger, Daniel J. Kruger
Background Products containing delta-8-THC became widely available in most of the USA following the 2018 Farm Bill and by late 2020 were core products of hemp processing companies, especially where delta-9-THC use remained illegal or required medical authorization. Research on experiences with delta-8-THC is scarce, some state governments have prohibited it because of this lack of knowledge....